NCT05369195 Cerebral Protection in Transcatheter Left Atrial Appendage Occlusion
| NCT ID | NCT05369195 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Silesian Centre for Heart Diseases |
| Condition | Atrial Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2023-05-26 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2023-05-26 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to assess the effect of the use of neuroprotection in transcutaneous occlusion of the left atrial appendage in patients with atrial fibrillation on the risk of perioperative silent brain ischemia and associated cognitive impairment and depression.
Eligibility Criteria
Inclusion Criteria: 1. 18 Years and older 2. Subject able to provide signed informed consent. 3. Documented permanent, persistent, or paroxysmal atrial fibrillation 4. CHA2DS2VASc risk of stroke ≥2 5. At least one of the following criteria: 1. Contraindications to the use of anticoagulants, 2. HSBLED bleeding risk ≥3 Exclusion Criteria: 1. Serious mental diseases, particularly: dementia syndrome of any etiology, schizophrenia,schizoaffective disorders, bipolar disorder 2. History of ischemic stroke 3. Chronic abuse of alcohol or any other psychoactive substances except for nicotine 4. long-term therapy with benzodiazepines 5. The use of antidepressants in 3 months prior inclusion. 6. Previous infections of the central nervous system, including neuroborreliosis 7. Parkinson's disease 8. Huntington's chorea 9. Creutzfeld-Jakob disease 10. Pick's disease 11. Significant atherosclerosis of the cephalic arteries (\> 70% LCCA or the brachiocephalic trunk) 12. Strictures, ectasias, dissection or aneurysms at the exit of the LCCA or the brachiocephalic trunk from the aorta and up to 3 cm above 13. Advancement of vascular changes in DW MRI of the head, grade 3 on the Fazekas scale 14. Presence of a thrombus or tumours of a different nature in the left atrium or its ear 15. Presence of a thrombus in the left ventricle 16. Left atrial appendage anatomy preventing the use of occluders to close the left atrium appendage 17. The presence of mechanical heart valve prostheses 18. The state after the operative closure of the defect in the atrial septum 19. Condition after closing the defect in the interatrial septum with the use of occluders 20. Active infective endocarditis 21. Presence of devices and prostheses that prevent the performance of MRI (pacemakers, clips in the CNS) 22. Status after oesophagal surgery 23. Esophageal diverticula 24. Esophageal varices\> grade 3 25. Allergic to contrast agents 26. A contraindication to use antiplatelet drugs 27. Diagnosis of neoplastic disease with estimated survival beyond 1 year 28. Clininally evident hypothyroidism and hyperthyroidism 29. Klaustrofobia 30. Pregnancy 31. AIDS 32. Participation in other drug research studies 33. The presence of circumstances or any medical condition the Investigator considers problematic for subject inclusion, or test results that may couse problems to provide reliable, acurate to interpretation results
Contact & Investigator
Zbigniew F Kalarus, Prof.
PRINCIPAL INVESTIGATOR
Silesian Centre for Heart Diseases in Zabrze
Frequently Asked Questions
Who can join the NCT05369195 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05369195 currently recruiting?
Yes, NCT05369195 is actively recruiting participants. Contact the research team at w.streb@sccs.pl for enrollment information.
Where is the NCT05369195 trial being conducted?
This trial is being conducted at Katowice, Poland, Krakow, Poland, Poznan, Poland, Warsaw, Poland and 2 additional locations.
Who is sponsoring the NCT05369195 clinical trial?
NCT05369195 is sponsored by Silesian Centre for Heart Diseases. The principal investigator is Zbigniew F Kalarus, Prof. at Silesian Centre for Heart Diseases in Zabrze. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.